Meeting
2024 ASCO Annual Meeting
Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.
Authors
Ardaman Shergill
Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL
Ardaman Shergill , Chih-Yi Liao , Mohamed I. Elsaid , Tareq Al Baghdadi , Yan Ji , Diane Feldman , Suzanne George , Eileen M. O'Reilly , Jeffrey A. Meyerhardt , Stephanie A. Berg , Gary K. Schwartz , Pamela N. Munster , Tanios S. Bekaii-Saab , Ghassan K. Abou-Alfa , Rachna T. Shroff , Geoffrey Ira Shapiro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05564403
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS4196)
DOI
10.1200/JCO.2024.42.16_suppl.TPS4196
Abstract #
TPS4196
Poster Bd #
168a
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.
First Author: Naminatsu Takahara
Poster
2016 ASCO Annual Meeting
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
First Author: Heinz-Josef Lenz
Poster
2016 Gastrointestinal Cancers Symposium
MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Heinz-Josef Lenz
Poster
2014 ASCO Annual Meeting
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.
First Author: Manish Sharma